Dociparstat sodium

Drug Profile

Dociparstat sodium

Alternative Names: CX-01; ODSH; PGX-100; PGX-ODSH-2013-AML-1

Latest Information Update: 21 Apr 2017

Price : $50

At a glance

  • Originator ParinGenix
  • Developer Cantex Pharmaceuticals
  • Class Anti-inflammatories; Antineoplastics; Heparins; Ischaemic heart disorder therapies
  • Mechanism of Action Cathepsin G inhibitors; HMGB1 protein inhibitors; Leucocyte elastase inhibitors; P selectin inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Acute myeloid leukaemia; Myelodysplastic syndromes; Pancreatic cancer
  • Phase I Brain injuries
  • Clinical Phase Unknown Lung cancer; Solid tumours
  • Discontinued Acute coronary syndromes; Chronic obstructive pulmonary disease; Myocardial infarction; Reperfusion injury; Thrombocytopenia

Most Recent Events

  • 19 Apr 2017 Phase-II clinical trials in Myelodysplastic syndromes in USA (IV)
  • 07 Apr 2017 Discontinued - Phase-I for Thrombocytopenia (Combination therapy, In children, In adults) in USA (IV)
  • 07 Apr 2017 Phase-I clinical trials in Brain injuries in USA (IV) (Cantex Pharmaceuticals pipeline, April 2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top